Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.
暂无分享,去创建一个
Jih-Luh Tang | Chia-Wen Liu | Shang-Yi Huang | Shang-Ju Wu | Hwei-Fang Tien | Hsin-An Hou | Yi-Chang Chang | Szu-Chun Hsu | Wen-Chien Chou | M. Yao | Yao-chang Chen | Chien-Yuan Chen | W. Tsay | Shang‐Yi Huang | Jih-Luh Tang | H. Tien | Chien-Yuan Chen | Ming Yao | Yao-Chang Chen | H. Hou | W. Chou | Woei Tsay | S. Hsu | Mei-Hsuan Tseng | Chi-Fei Huang | Fen-Yu Lee | Bor-Shen Ko | Yen-Ning Huang | Ming-Chi Liu | Shang-Ju Wu | F. Lee | Yi-Chang Chang | B. Ko | Chia‐Wen Liu | Mei‐Hsuan Tseng | Chi‐Fei Huang | Ming‐Chih Liu | Yen-Ning Huang
[1] M. Yao,et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. , 2006, Cancer research.
[2] M. Lübbert,et al. Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alpha. , 2005, Leukemia.
[3] A. Marchetti,et al. IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high‐grade gliomas but not in other solid tumors , 2009, Human mutation.
[4] S. Fröhling,et al. Genetics of myeloid malignancies: pathogenetic and clinical implications. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Jih-Luh Tang,et al. Characterization of CEBPA Mutations in Acute Myeloid Leukemia: Most Patients with CEBPA Mutations Have Biallelic Mutations and Show a Distinct Immunophenotype of the Leukemic Cells , 2005, Clinical Cancer Research.
[6] Paola Fazi,et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.
[7] Kun-Liang Guan,et al. Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α , 2009, Science.
[8] M. Lübbert,et al. Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1α that augments transcriptional activity of CCAAT/enhancer-binding protein-α , 2005, Leukemia.
[9] Ken Chen,et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.
[10] Y C Chen,et al. Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan. , 1995, Cancer genetics and cytogenetics.
[11] T. Lister,et al. Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML , 2007, Leukemia.
[12] Hua Yan,et al. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells. , 2005, Haematologica.
[13] Amy E. Hawkins,et al. DNA sequencing of a cytogenetically normal acute myeloid leukemia genome , 2008, Nature.
[14] J. Uhm. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .
[15] D. Gilliland,et al. Genetics of myeloid leukemias. , 2003, Annual review of genomics and human genetics.
[16] H. Tien,et al. Characterization of acute myeloid leukemia with PTPN11 mutation: the mutation is closely associated with NPM1 mutation but inversely related to FLT3/ITD , 2008, Leukemia.
[17] G. Reifenberger,et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] B. Ko,et al. RUNX1 gene mutation in primary myelodysplastic syndrome – the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome , 2007, British journal of haematology.
[19] R. McLendon,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[20] K. Hoang-Xuan,et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Guoqiang Chen,et al. Hypoxia-inducible factor-1α-induced differentiation of myeloid leukemic cells is its transcriptional activity independent , 2008, Oncogene.
[22] T. Tominaga,et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients , 2009, Cancer science.